Quick Summary
- Positive Phase 1 MAD Results: Statistically significant body weight reductions vs. placebo across multiple dose cohorts, validating the amylin receptor pathway.
- Differentiated Tolerability Profile: Lower nausea burden vs. GLP-1 comparators addresses the #1 adherence barrier in the obesity drug class.
- Phase 2 Advancement Planned: AbbVie intends to move into a Phase 2 dose-ranging study, a key pipeline milestone for its cardiometabolic franchise.
AbbVie (NYSE: ABBV) announced on March 9, 2026, positive topline results from a Phase 1 multiple ascending dose (MAD) study evaluating ABBV-295 the company’s investigational long-acting amylin analog in adults with overweight or obesity.
The results confirm that ABBV-295 achieves statistically significant reductions in body weight compared to placebo, while demonstrating a differentiated and favorable tolerability profile. This combination is particularly compelling in a competitive obesity therapeutics market increasingly dominated by GLP-1 receptor agonists, where gastrointestinal side effects remain the primary driver of patient discontinuation.
The announcement marks a significant milestone for AbbVie’s emerging cardiometabolic pipeline, positioning ABBV-295 as a potential best-in-class or first-in-class asset leveraging the amylin pathway a mechanism of action entirely distinct from the GLP-1/GIP pathways exploited by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
Background: The Amylin Pathway
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It plays a crucial, multifaceted role in regulating postprandial physiology and has long been recognized as a pharmacologically rich target for metabolic disease.
Key physiological roles relevant to ABBV-295:
- Central satiety signaling via area postrema and nucleus of the solitary tract is independent of GLP-1 pathways.
- Appetite suppression reduces meal-initiated food intake through distinct hypothalamic circuits.
- Gastric emptying modulation to dampen postprandial glucose excursions.
- Glucagon suppression during meals contributes to glycemic control.
- Synergy with GLP-1 agonists when co-administered, suggesting a compelling combination therapy potential.
Despite this validated biology, the development of amylin-based therapies has historically been hampered by aggregation propensity, a formulation challenge that limited the original amylin analog pramlintide (Symlin) to short-acting, multiple-daily-injection regimens with modest efficacy. ABBV-295 represents a next-generation long-acting amylin analog engineered to overcome these barriers through novel molecular stabilization, enabling once-weekly subcutaneous administration.
Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment
Phase 1 MAD Study: Design
The Phase 1 MAD study was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of ABBV-295 in adult participants with overweight or obesity (BMI ≥27 kg/m²).
The MAD design involving repeated doses at sequentially higher levels with safety review between cohorts is the gold-standard methodology for establishing a safe and efficacious dose range prior to Phase 2 dose-selection trials. It informs maximum tolerated dose (MTD), no-observed-adverse-effect level (NOAEL), and optimal pharmacological dose (OPD) determinations.
Study objectives:
- Primary: Safety and tolerability of ABBV-295 across multiple ascending dose levels
- Secondary: PK/PD characterization following once-weekly subcutaneous dosing
- Exploratory: Effect of ABBV-295 on body weight and key cardiometabolic biomarkers
Clinical Data Summary
| Parameter | Finding | Clinical Significance |
|---|---|---|
| Study Design | Phase 1, Randomized, Double-blind, Placebo-controlled MAD | Gold-standard early-phase design; minimizes bias |
| Molecule | ABBV-295 — long-acting amylin analog (weekly SC injection) | Once-weekly dosing improves adherence vs. daily injectables |
| Population | Adults with overweight/obesity (BMI ≥27 kg/m²) | Broad phenotype; real-world commercial relevance |
| Primary Endpoint | Safety, tolerability & PK/PD profile | Foundation for Phase 2 dose selection |
| Weight Reduction | Statistically Significant vs. placebo across dose cohorts | Validates amylin pathway as viable obesity target in humans |
| Tolerability | Favorable; GI AEs mild-to-moderate, transient | Differentiated from GLP-1 receptor agonist class profile |
| Nausea | Lower relative nausea vs. GLP-1 comparators (historical) | Addresses #1 adherence barrier in obesity drug class |
| SAEs | None Attributed to ABBV-295 | Supports dose escalation and Phase 2 entry |
| Biomarkers | Improvements in fasting glucose & lipid parameters (exploratory) | Signals cardiometabolic benefit beyond weight reduction |
| Dosing | Once-Weekly SC | Competitive with semaglutide and tirzepatide convenience |
| Next Steps | Phase 2 dose-ranging study planned | Accelerated development timeline supported by robust Phase 1 package |
Key Efficacy Findings
The centerpiece of AbbVie’s announcement was the achievement of statistically significant body weight reduction versus placebo across multiple dose cohorts, a result not universally expected from a Phase 1 MAD study, which is primarily powered for safety rather than efficacy.
This early efficacy signal meaningfully de-risks the clinical development program and provides confidence in the biological activity of ABBV-295 in humans. The dose-dependent relationship between ABBV-295 exposure and weight loss suggests a robust pharmacodynamic effect consistent with amylin-mediated satiety mechanisms.
Cardiometabolic biomarker improvements:
Beyond weight reduction, exploratory analyses pointed to improvements in fasting glucose and lipid parameters indicating potential cardiometabolic benefits that could strengthen labeling and commercial positioning if confirmed in Phase 2/3 trials.
PK/PD profile
ABBV-295 demonstrated a pharmacokinetic profile consistent with once-weekly dosing, with an exposure-response relationship that supports dose selection for Phase 2 development. The long-acting formulation technology appears to have successfully addressed the aggregation challenges that limited prior amylin analogs.
Read More: New anti-obesity drugs reduces weight-loss surgery numbers
Tolerability: The Key Differentiator
In the obesity therapeutics market, tolerability, particularly gastrointestinal tolerability, is increasingly recognized as a critical driver of real-world adherence and commercial success. GLP-1 receptor agonists, while highly effective, carry high rates of nausea, vomiting, and constipation that limit dose escalation and drive discontinuation in a meaningful proportion of patients.
ABBV-295’s Phase 1 MAD data revealed a tolerability profile that may represent a genuine clinical and commercial differentiator:
- GI adverse events were generally mild-to-moderate in severity and transient in nature.
- Nausea rates appeared lower relative to historical GLP-1 comparators at equivalent efficacy dose ranges.
- No serious adverse events attributed to ABBV-295 were reported in the topline data.
- The safety profile was consistent across dose cohorts, supporting dose escalation into Phase 2.
AstraZeneca’s Enhertu EU Approval: Enhertu Plus Pertuzumab Cleared as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer, marking AstraZeneca and Daiichi Sankyo's first new EU […]
Lilly Merida Biosciences Acquisition: Eli Lilly to Pay $2.875 Billion for Precision Autoantibody Therapies
Eli Lilly will pay up to $2.875 billion to acquire Merida Biosciences, gaining a precision antibody-degradation platform led by Phase 1 candidate MER511 for Graves' […]
Roche Vabysmo PCV Study Shows Sustained Two-Year Results in Difficult-to-Treat nAMD Subtype
New two-year data from Roche's Phase IIIb/IV SALWEEN trial show that Vabysmo (faricimab) delivers durable vision gains and disease control in Asian patients with polypoidal […]
Development Pathway
Following the positive Phase 1 MAD results, AbbVie has indicated its intention to advance ABBV-295 into a Phase 2 dose-ranging study. The Phase 2 program will be designed to:
- Confirm dose-response relationships for weight loss and metabolic endpoints in a larger, more representative population
- Evaluate long-term safety and tolerability over extended treatment duration (typically 16–52 weeks)
- Explore ABBV-295 in combination with GLP-1 receptor agonists to assess additive or synergistic efficacy
- Identify target patient populations, particularly those intolerant to or inadequately responding to existing GLP-1 therapies
Subject to Phase 2 results, the program could advance to pivotal Phase 3 trials targeting regulatory submission by the late 2020s. The strong Phase 1 data package supports an expedited development timeline, and AbbVie’s commercial infrastructure, built over decades of blockbuster drug launches, provides a meaningful go-to-market advantage should ABBV-295 reach approval.
Last Modified:
